ClinicalTrials.gg
Active, not recruitingNCT04960709VOLGAUpdated Jun 4, 2026

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

A Phase 3 interventional study of Durvalumab and Tremelimumab in Muscle Invasive Bladder Cancer, sponsored by AstraZeneca. Active, not recruiting at 196 sites in 25 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.

Enrollment
3rd of 19
712 · median 39
Started
2021
with 3 others
Phase 3
3 of 19
none open now
Primary completion
2026-03
later than 2 of 11 live
Registered
14th of 19
by date
Lead sponsor
5 of 19
AstraZeneca

Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 14th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing durvalumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplatin based chemotherapy Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer.

The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC).

VOLGA trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 677 patients, who will receive triplet combination, duplet combination or currently approved SOC in the main study. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system.

In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Enfortumab Vedotin and 2 cycles of Tremelimumab or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will receive either adjuvant Durvalumab or adjuvant Durvalumab and 1 cycle of Tremelimumab.

Read the detailed description

Not provided

03

Conditions studied

  • Muscle Invasive Bladder Cancer

Keywords

  • Bladder Cancer
  • Immunotherapy
  • PD-L1
  • Durvalumab (MEDI4736)
  • Tremelimumab
  • Enfortumab Vedotin (PADCEV)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented muscle-invasive UC of the bladder.
  • Participants with transitional cell and mixed transitional/non-transitional cell histologies;
  • Participants with MIBC clinical tumor (T) stage T2-T4aN0/1M0 or UC of the bladder with clinical state T1N1M0 (participants with T1 stage are allowed only with N1 disease)
  • Participants should also have not received prior systemic chemotherapy or immunotherapy for the treatment of MIBC or bladder UC.
  • Medically fit for cystectomy and able to receive therapy;
  • Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC;
  • performance status of 0,1,2 at enrollment.
  • Availability of tumor sample prior to study entry;
  • Must have a of at least 12 weeks at randomization.
  • Cisplatin-ineligible, following criteria based on Galsky et al 2011 OR Refuse cisplatin based chemotherapy (must be documented in the medical records)

Exclusion criteria

Exclusion criteria:

  • Evidence of lymph node (N2+) or TCC/UC disease at the time of screening.
  • Active infection
  • Uncontrolled intercurrent illness
  • Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other , anti--PD-1, anti PD-L1, or anti-PD-L2 antibodies.
  • Current or prior use of medication within 14 days before the first dose of IPs.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
712 participants (actual)

Study arms

  • Experimental
    Durvalumab + Tremelimumab + Enfortumab Vedotin

    Participants will receive 3 preoperative 21-day cycles of Durvalumab + Enfortumab Vedotin and 2 cycles of Tremelimumab, followed by radical cystectomy, followed by 1 cycle of postoperative Tremelimumab and 9 cycles of Durvalumab. Each postoperative cycle is 28 days.

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Enfortumab Vedotin · Procedure: Radical Cystectomy

  • Experimental
    Durvalumab + Enfortumab vedotin

    Participants will receive 3 preoperative 21-day cycles of Durvalumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 9 cycles of Durvalumab. Each postoperative cycle is 28 days.

    Drug: Durvalumab · Drug: Enfortumab Vedotin · Procedure: Radical Cystectomy

  • Active comparator
    Cystectomy with or without approved Adjuvant Therapy.

    Participants may receive SoC (nivolumab approved as adjuvant treatment for MIBC based on high risk criteria) per approved label in the country OR Participants receive standard of care surgery (radical cystectomy) alone.

    Procedure: Radical Cystectomy

Interventions

  • Anti- PD-L1 Antibody

    Also known as: IMFINZI, MEDI4736

  • Human IgG2 mAb

  • Nectin-4-directed antibody and microtubule inhibitor conjugate

    Also known as: PADCEV

  • ProcedureRadical Cystectomy

    For cisplatin-ineligible or cisplatin-refusal patients

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part)

    Frequency of Adverse Events.

    Time frame: At completion of study treatment by the last patient and at 3 months.

  2. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (blood pressure in mmHg) (Safety Run-In part)

    Time frame: Up to 84 months

  3. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (pulse rate) in beats per minute (Safety Run-In part)

    Time frame: Up to 84 months

  4. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (respiration rate) in breaths per minute (Safety Run-In part)

    Time frame: Up to 84 months

  5. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (temperature) in degrees Celsius (Safety Run-In part)

    Time frame: Up to 84 months

  6. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by liver function (Safety Run-In part)

    Clinical chemistry will be assessed by liver function assessment (ALT, AST, albumin, total bilirubin measured in units per dL)

    Time frame: Up to 84 months

  7. Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by kidney function (Safety Run-In part)

    Clinical chemistry will be assessed by kidney function assessment in mg/dL

    Time frame: Up to 84 months

  8. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by thyroid function (Safety Run-In part)

    Clinical chemistry will be assessed by thyroid function assessment in units per mL.

    Time frame: Up to 84 months

  9. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in haematology (Safety Run-In part)

    Hematology will be assessed by white cell count, platelet count, absolute neutrophil count and absolute lymphocyte count.

    Time frame: Up to 84 months

  10. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as as assessed by ECG (pulse rate) (Safety Run-In part)

    Time frame: Up to 84 months

  11. Changes in WHO/ECOG performance status (Safety Run-In part)

    Eastern Cooperative Oncology Group (ECOG) performance status scale range 0 to 5, where 0 is fully active, able to carry on all pre disease performance without restriction - best outcome and 5 -death - worst outcome.

    Time frame: Up to 84 months

  12. Compare efficacy of durvalumab + tremelimumab + EV (Arm 1) relative to cystectomy (Arm 3) and durvalumab + EV (Arm 2) relative to cystectomy (Arm 3) on EFS (Main Study)

    Event-free survival (EFS;) is defined as the time from randomization to the first occurrence of any of the following events: recurrence of disease post-radical cystectomy, the first documented progression in participants who did not receive radical cystectomy, failure to undergo radical cystectomy in participants with residual disease, or death due to any cause, up to 3 years.

    Time frame: Up to 3 years

Secondary outcomes

  1. 1. To evaluate the efficacy of durvalumab + tremelimumab + EV on pCR rate (Safety Run-in part)

    Pathologic complete response (pCR) rate is defined as the number of participants whose pathological staging was T0N0M0 as assessed per local pathology and central independent review using specimens obtained via cystectomy, at 3 years.

    Time frame: 3 years

  2. 2. To evaluate the efficacy of durvalumab + tremelimumab + EV on EFS (Safety Run-in part)

    Event-free survival (EFS;) is defined as the time from randomization to the first occurrence of any of the following events: recurrence of disease post-radical cystectomy, the first documented progression in participants who did not receive radical cystectomy, failure to undergo radical cystectomy in participants with residual disease, or death due to any cause, up to 3 years.

    Time frame: 3 years

  3. 3. Pathologic complete response (pCR) rates at time of cystectomy in Arm1 vs Arm3 and Arm 2 vs Arm 3 (Main Study part)

    Pathologic complete response (pCR) rate is defined as the number of participants whose pathological staging was T0N0M0 as assessed per local pathological review using specimens obtained via cystectomy, at 3 years.

    Time frame: 3 years

  4. 4. Overall survival (Safety Run-in and Main Study part)

    Overall Survival is defined as length of time from randomization until the date of death due to any cause, whichever came first, assessed up to 5 years.

    Time frame: Up to 5 years

  5. 5. EFS at 24 months (EFS24) (Safety Run-in and Main Study part)

    EFS24 is defined as proportion of participants alive and event-free at 24 months

    Time frame: Up to 24 months

  6. 6. Overall survival rate at 5 years (Safety Run-in and Main Study part)

    The proportion of participants alive at 5 years (OS5) is defined as the Kaplan-Meier estimate of OS at 5 years after randomization

    Time frame: At 5 years

  7. 7. Disease-free survival (DFS) (Safety Run-in and Main Study part)

    DFS is defined as time from radical cystectomy to recurrence or death, whichever came first, assessed up to 5 years.

    Time frame: Up to first recurrence of disease or death up to 5 years

  8. 8. Pathologic downstaging (pDS) rate-to < pT2 (Safety Run-in and Main Study part)

    pDS rate is defined as the rate of downstaging to \< pT2, including pT0, pTis, pTa, pT1, and N0

    Time frame: 3 years

  9. 9. Disease-specific survival (DSS) (Safety Run-in and Main Study part)

    DSS is defined as time from randomization until death due to bladder cancer, assessed up to 5 years.

    Time frame: from randomization until death due to bladder cancer up to 5 year.

  10. 10. EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire) (Safety Run-in and Main Study part)

    Time frame: from baseline and time to definitive clinically, assessed up to 5 years

  11. 11. Immunogenicity of durvalumab when used in combination with Tremelimumab as measured by presence of antidrug antibodies (ADA) (Safety Run-in and Main Study part)

    Time frame: At 3 months after last dose of durvalumab and tremelimumab

  12. 12. Time to maximum observed serum concentration (tmax) of durvalumab and tremelimumab (Safety Run-in and Main Study part)

    Time frame: At 3 months after last dose of durvalumab and tremelimumab

  13. 13. Metastasis-free survival (MFS) (Safety Run-in and Main Study part)

    MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first, up to approximately 48 months.

    Time frame: From randomization until the first recognition of distant metastases or death, up to approximately 48 months.

07

Study locations

196 sites
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Maywood, Illinois 60153, United States
  • Research Site
    Indianapolis, Indiana 46250, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Scarborough, Maine 04074, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Brighton, Michigan 48114, United States
  • Research Site
    Jackson, Mississippi 39213, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Saddle Brook, New Jersey 07663, United States
  • Research Site
    Brooklyn, New York 11219, United States
  • Research Site
    Buffalo, New York 14263, United States
  • Research Site
    New York, New York 10040, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Knoxville, Tennessee 37932, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Irving, Texas 75063, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Buenos Aires, C1431FWO, Argentina
  • Research Site
    CABA, C1426ANZ, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1280AEB, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1419AHL, Argentina
  • Research Site
    Pergamino, B2700CPM, Argentina
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Krems, 3500, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1020, Austria
  • Research Site
    Wiener Neustadt, 2700, Austria
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Fortaleza, 60135-237, Brazil
  • Research Site
    Porto Alegre, 90035-001, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Rio de Janeiro, 22250-905, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    Săo Paulo, 03162-065, Brazil
  • Research Site
    Uberlândia, 38408-150, Brazil
  • Research Site
    Abbotsford British Columbia, British Columbia V2S 3N5, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Québec, Quebec G1R 2J6, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Santiago, 7500653, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Amiens, 80090, France
  • Research Site
    Bayonne, 64100, France
  • Research Site
    Clermont-Ferrand, 63011, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Marseille, 13385, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Nice, 06189, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Quint-Fonsegrives, 31130, France
  • Research Site
    Saint-Priez En Jarez, 42270, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Suresnes, 92151, France
  • Research Site
    Vandœuvre-lès-Nancy, 54519, France
  • Research Site
    Bielefeld, 33611, Germany
  • Research Site
    Bochum, 44791, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Giessen, 35392, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Herne, 44625, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Reutlingen, 72766, Germany
  • Research Site
    Ulm, 89075, Germany
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Maroussi, Athens, 15125, Greece
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Hadera, 38100, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 9103102, Israel
  • Research Site
    Jerusalem, 9112001, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Meldola, 47014, Italy

Showing the first 100 of 196 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2026, 54 months.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 54 months is close to that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Jul 14, 2021
StartActual
Aug 5, 2021
Primary completionActual
Mar 2, 2026
CompletionEst.
Sep 8, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04960709
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
Aug 5, 2021
Primary completion
Mar 2, 2026
Completion
Sep 8, 2028 (estimated)
Last update
Jun 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab · Enfortumab vedotin

Start the discussion